Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Ask people to compile a list of the things wrong with modern cities, and the answer “a lack of whimsical commercial statuary” ...

Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners ...

Deal would redraw South Korean shipping map, creating combined fleet of 170 high-value vessels, domestic report says ...